A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE. The study tests different doses of BI 3000202 and aims to find the best dose for people with this condition. Participants are put into 5 groups randomly, which means by chance. 4 groups get different doses of BI 3000202, and 1 group gets a placebo. Placebo tablets look like BI 3000202 tablets but do not contain any medicine. Participants take the tablets for 1 year. All participants also continue their regular treatment for SLE. Participants are in the study for a bit longer than 1 year. During this time, they visit the study site regularly. Doctors check the participants' health and take note of any unwanted effects. They also compare the results between the groups to see if the treatment works.

NCT Number	NCT07409181
Lead Sponsor	Boehringer Ingelheim
Conditions	Systemic Lupus Erythematosus
Enrollment	405 participants
Start Date	2026-04-20
Primary Completion	2029-02-04 (estimated)
Study Completion	2029-07-08 (estimated)
Updated on ClinicalTrials.gov	2026-08-06